Ginkgo Bioworks

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line, with revenue of $20.2M significantly trailing the expected $24.9M. While GAAP EPS of -$0.75 beat the -$1.32 expectation, this was largely driven by a $24.5M one-time gain from the Biosecurity divestiture rather than core operational strength. Cell Engineering revenue fell 48% YoY, reflecting reduced program scope with major agricultural and pharma partners, though management successfully narrowed operating losses through aggressive restructuring.